Clinical Trial Update: Phase I Study of AT13148, a Novel AGC Kinase Inhibitor [Phase 1]

View source ↗

Summary

Phase I study of AT13148, a novel AGC kinase inhibitor, in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• AT13148 (AT13148)

Snippet

Sponsor: Cancer Research UK | Conditions: Advanced Solid Tumours | Phase 1 | Status: COMPLETED